Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications
Feb 05, 2025•37 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
From high dose semaglutide to cagrisema launch dates, Dave Knapp discusses how the latest Novo Nordisk earnings call impacts patients.
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp
📱 Amazon Kindle Reader: https://amzn.to/4gAXrz4
📖Paperback: https://amzn.to/4gAXrz4
💊 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP
USE CODE "OTP10" to save 10%.
SOCIALS:
📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx
🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&_r=1
👾: https://discord.gg/ZHeUh7WV
📺: https://youtube.com/@ManOnTheMounjaro?feature=shared
❌: https://x.com/manonthepen?s=21
💻: https://www.onthepen.com
For the best experience, listen in Metacast app for iOS or Android